Podcasts about dlbcl

In this week's episode we'll learn about the role of autologous transplant for relapsed myeloma. In an updated analysis of the GMMG ReLApsE trial, salvage autologous transplant offered no survival benefit compared to control chemotherapy. These findings may have clinical implications in an era of alternative, and highly effective, treatment options. After that: Response to DDAVP, or desmopressin, in bleeding disorders. This study is the first large scale meta-analysis to assess the response rate to DDAVP in bleeding disorders. Authors provide new insights into determinants of response, which vary according to the disease type. Finally, turning to diffuse large B cell lymphoma. Germinal center B cells depend on the activity of DOT1 and EZH2 to maintain their pro-proliferative identity. New research shows that combined treatment with DOT1L and EZH2 inhibitors has synergistic activity in vitro.Featured Articles:Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trialDDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysisTargeting DOT1L and EZH2 synergizes in breaking the germinal center identity of diffuse large B-cell lymphoma

In this week's episode we'll learn about the role of interleukin-1 signaling in the bone marrow microenvironment in the development of myelodysplastic syndromes, the immune checkpoint regulator VISTA as a potential target for preventing graft-vs-host disease, and epcoritamab plus gemcitabine and oxaliplatin in transplant-ineligible relapsed/refractory diffuse large B-cell lymphoma.Featured Articles:IL-1R1 and IL-18 signals regulate mesenchymal stromal cells in an aged murine model of myelodysplastic syndromesTargeting cell-surface VISTA expression on allospecific naïve T cells promotes toleranceEpcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial

In this week's episode we'll learn about tracking the functional profile of aging platelets. Researchers demonstrate that over time, platelet function shifts away from hemostasis and toward a more immunomodulatory role. These finding could have important implications for transfusion medicine and certain platelet-related disease states. After that, use of odronextamab, a CD20×CD3 bispecific antibody, in patients with diffuse large B-cell lymphoma, or DLBCL, progressing after CAR T cell therapy. The study is the first to evaluate the efficacy and safety of this therapy in the post-CAR T cell treatment setting. Finally, we will recap findings from a study of a novel CAR T-cell product that utilizes specificity to two antigens common in diffuse large B-cell lymphoma.Featured Articles:Aging platelets shift their hemostatic properties to inflammatory functionsOdronextamab monotherapy in R/R DLBCL after progression with CAR T-cell therapy: primary analysis of the ELM-1 studyDissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma

Imugene Ltd CEO Leslie Chong talked with Kerry Stevenson at Proactive about the FDA's fast-track designation for its immunotherapy candidate, Azercell. The therapy, an allogeneic off-the-shelf CAR-T treatment, has shown promising results in patients with diffuse large B-cell lymphoma (DLBCL), a highly aggressive form of blood cancer. Chong highlighted that four out of seven patients treated with Azercell achieved complete response, meaning their cancer was no longer detectable. The longest response duration has now exceeded 11 months. “The FDA has recognised the importance of a product like this and has given us fast-track designation,” Chong stated. The FDA's fast-track status allows Imugene to expedite regulatory discussions and move towards potential commercialization more efficiently. The company sees this as a critical milestone, with Chong emphasising that the priority now is gathering sufficient data to advance towards registration studies. With an estimated 80,000 new DLBCL cases diagnosed annually in the US, Azercell could address a significant unmet need, especially for patients who have exhausted other treatment options. For more updates on Imugene and other biotech innovations, visit Proactive's YouTube channel. Don't forget to like this video, subscribe, and enable notifications for future content. #Imugene #Biotech #CancerResearch #FDA #CAR_T #Oncology #BloodCancer #DLBCL #MedicalBreakthrough #FastTrack #Immunotherapy

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EKV865. CME credit will be available until February 27, 2026.Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic Assessment and Off-the-Shelf Immunotherapy Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EKV865. CME credit will be available until February 27, 2026.Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic Assessment and Off-the-Shelf Immunotherapy Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EKV865. CME credit will be available until February 27, 2026.Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic Assessment and Off-the-Shelf Immunotherapy Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EKV865. CME credit will be available until February 27, 2026.Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic Assessment and Off-the-Shelf Immunotherapy Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EKV865. CME credit will be available until February 27, 2026.Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic Assessment and Off-the-Shelf Immunotherapy Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/EKV865. CME credit will be available until February 27, 2026.Addressing Unmet Needs for Better Outcomes in DLBCL: Leveraging Prognostic Assessment and Off-the-Shelf Immunotherapy Strategies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Pfizer.Disclosure information is available at the beginning of the video presentation.

Featuring slide presentations and related discussion from Prof Martin Hutchings, Dr Manali Kamdar, Dr Matthew Lunning and Prof Gilles Salles, including the following topics: Evolving Role of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Kamdar (0:00) Case: A 61-year-old man with Stage IV non-GCB DLBCL receives R-CHOP but experiences disease progression 8 months later (30:39) Case: A 68-year-old man with double-hit DLBCL who experiences disease progression on chemotherapy and second-line CAR T-cell therapy receives glofitamab (39:22) Incorporation of Bispecific Antibody Therapy into DLBCL Management — Prof Hutchings (45:25) Case: A 42-year-old man with progressive DLBCL refractory to 2 lines of therapy receives glofitamab with a durable response (1:07:30) Case: An 81-year-old woman with multiregimen-refractory DLBCL experiences a prolonged response to epcoritamab (1:14:25) Case: A 69-year-old man with follicular lymphoma transformed to DLBCL and refractory to 3 lines of treatment receives glofitamab (1:21:48) Selection and Sequencing of Other Available Therapies for Relapsed/Refractory (R/R) DLBCL — Prof Salles (1:24:37) Case: An 82-year-old woman with follicular lymphoma transformed to DLBCL receives tafasitamab/lenalidomide (1:42:05) Case: A 69-year-old man with urinary bladder carcinoma and recurrent GCB DLBCL receives loncastuximab tesirine (1:46:26) Promising Investigational Approaches for Patients with R/R DLBCL — Dr Lunning (2:00:37) Case: An 80-year-old woman with multiregimen-refractory GCB DLBCL seeks treatment requiring minimal clinic visits and receives loncastuximab tesirine (2:15:59) Case: A 54-year-old man with primary refractory non-GCB DLBCL receives CAR T-cell therapy, and follow-up imaging on day 29 demonstrates a Deauville score of 4 (2:25:22) CME information and select publications

Welcome to another episode of the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain are joined by Dr. Pallawi Torka from Memorial Sloan Kettering Cancer Center to discuss the latest highlights from ASH 2024, focusing on key studies in lymphoma. In this episode, we dive into: •⁠  ⁠POLARIX Study: An update on the POLARIX trial, exploring the use of Polatuzumab in frontline diffuse large B-cell lymphoma (DLBCL) and its impact on progression-free survival (PFS). •⁠  ⁠inMIND Study: A look at the promising results of the inMIND study, which evaluates the combination of Tafasitamab with Lenalidomide and Rituximab in the second-line setting for follicular lymphoma. •⁠  ⁠Triangle Study: Insights into the evolving role of transplant in mantle cell lymphoma and the implications of BTK inhibitors in treatment. •⁠  ⁠ENRICH Study: Discussion on the potential of Ibrutinib combined with Rituximab in the first-line setting and its comparison to traditional chemoimmunotherapy. Join us as we unpack these practice-changing studies, discuss their implications for clinical practice, and share insights on managing side effects associated with new therapies. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology research and practice! #OncologyBrothers #ASH2024 #Lymphoma #CancerResearch #Podcast

Dr Jennifer Crombie from Dana-Farber Cancer Institute, Prof Martin Hutchings from Copenhagen University Hospital, Dr Matthew Lunning from the University of Nebraska Medical Center, Dr Tycel Phillips from City of Hope and moderator Dr Jeremy S Abramson from Massachusetts General Hospital discuss recently updated data on the role of CAR T-cell therapy and bispecific antibodies in the management of diffuse large B-cell, mantle cell and follicular lymphoma. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/ASHCART24).

In this episode, we discussed the top abstracts in lymphoma and CLL presented at the ASH 2024 annual meeting in San Diego with Dr. David A Russler-Germain from Washington University. Here are the key abstracts we discussed: 1. 3 RCTs in Mantle Cell Lymphoma: a) Update on TRIANGLE: https://ash.confex.com/ash/2024/webprogram/Paper200735.htmlb) ENRICT Trial (Continuous Ibrutinib-Rituximab vs CIT [R-CHOP or BR]): https://ash.confex.com/ash/2024/webprogram/Paper199710.htmlc) ECOG-ACRIN EA4151 Trial (Auto-HCT vs Rituximab maintenance alone in patients with undetectable MRD after induction): https://ash.confex.com/ash/2024/webprogram/Paper212973.html2. DLBCL: a) Update on POLARIX Trial: https://ash.confex.com/ash/2024/webprogram/Paper197938.htmlb) Predictive Value of Cell-of-Origin Subtype By Hans Algorithm in DLBCL Patients Receiving Polatuzumab Vedotin: https://ash.confex.com/ash/2024/webprogram/Paper202153.htmlc) COALITION trial: https://ash.confex.com/ash/2024/webprogram/Paper204930.html3. Follicular Lymphoma: a) Phase 3 inMIND trial (Tafasitamab + R2 vs Placebo + R2): https://ash.confex.com/ash/2024/webprogram/Paper212970.htmlb) Loncastuximab tesirine with rituximab in patients with R/R FL: https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00345-4/abstract4. CLL: a) AMPLIFY Trial (Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy in 1st line CLL): https://ash.confex.com/ash/2024/webprogram/Paper200701.html5. Hodgkin Lymphoma: a) Pembrolizumab Maintenance Instead of Auto-HCT for R/R HL: https://ash.confex.com/ash/2024/webprogram/Paper202537.html

Authors Gloria Iacoboni and María Pérez Raya outline the management of a patient receiving Chimeric antigen receptor (CAR) T-cell therapy for relapsed/refractory (r/r) diffuse large B cell lymphoma (DLBCL). CAR T-cell therapy is effective in the treatment of patients with DLBCL, even those with high-grade disease. However, it has a unique safety profile, including cytokine-release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS), and robust management of these events are important to maximize benefits. This vodcast audio is published open access in Oncology and Therapy as a vodcast article with visual elements and is fully citeable. You can access the original published vodcast article through the Oncology and Therapy website and by using this link: https://link.springer.com/article/10.1007/s40487-024-00319-x. All conflicts of interest can be found online. This vodcast audio is intended for medical professionals. Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong joins Proactive's Tylah Tully to provide a company update, including launching the first Australian site for the Phase 1b clinical trial of its azer-cel (azercabtagene zapreleucel) allogeneic CAR T-cell therapy. The Royal Prince Alfred Hospital in Sydney will lead Australian patient recruitment, with enrolment beginning in November 2024, marking Australia's only active trial for allogeneic CAR T-cell therapy in treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL). This Australian expansion offers patients access to azer-cel, addressing critical treatment gaps for DLBCL, an aggressive form of non-Hodgkin's lymphoma. Chong emphasised the importance of local access to this innovative therapy. Imugene's US trials have shown promising results, with three patients achieving complete responses, two of whom received a combination of azer-cel with lymphodepletion and interleukin-2 (IL-2), showing durable responses extending beyond 90 and 120 days. The company has also dosed the first patient in the intratumoural (IT) injection combination arm of its OASIS Phase 1 clinical trial for onCARlytics (CF33-CD19). This trial aims to test the efficacy and safety of Imugene's CD19-expressing oncolytic virotherapy in advanced or metastatic solid tumours. The first colorectal cancer patient was treated at Northwestern University, and the trial is expected to enrol up to 40 participants with various advanced cancers. #ProactiveInvestors #Imugene #ASX  #Oncology #CAR_TCellTherapy #AzerCel #Vaxinia #ClinicalTrials #CancerResearch #Immunotherapy #DLBCL #HER2 #BileCancer #Biotechnology #ASX #FDAApproval #OrphanDrug #FastTrack #BiotechInvesting #OncolyticVirotherapy #CancerTreatment #CashPosition

In diesem „Expertendialog“ sprechen wir mit Prof. Frederik Damm, ein führender Spezialist auf dem Gebiet der Lymphome und geschäftsführender Oberarzt der Medizinischen Klinik mit dem Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie an der Charité Berlin. Er gibt uns tiefgehende Einblicke in die Diagnostik und Therapie des diffus großzelligen B-Zell-Lymphoms (DLBCL). Welche aktuellen Therapieempfehlungen gibt es und wie könnten zukünftige Behandlungsansätze aussehen? Erfahren Sie mehr über die neuesten Entwicklungen und wie moderne Technologien die Behandlung verbessern können.

Featuring perspectives from Dr Christopher Flowers, Prof Grzegorz S Nowakowski and Dr Laurie H Sehn, moderated by Dr Flowers, including the following topics: Introduction (0:00) Front-Line Management of Diffuse Large B-Cell Lymphoma (DLBCL) — Dr Sehn (1:56) Case: A woman in her late 40s with epidural DLBCL and a compression fracture (Dr Flowers) (12:45) Case: A woman in her late teens with primary intestinal large B-cell lymphoma (Dr Nowakowski)(16:51) Integration of Novel Agents into the Care of Patients with Relapsed/Refractory DLBCL — Dr Flowers (21:14) Case: A man in his late 70s diagnosed with DLBCL with recurrent disease (Dr Nowakowski) (29:38) Case: A woman in her mid 70s with multiple comorbidities diagnosed with DLBCL (Dr Sehn) (36:17) Bispecific Antibody Therapy for DLBCL — Dr Nowakowski (39:39) Case: A man in his late 50s with no comorbidities with recurrent DLBCL (Dr Sehn) (50:50) Case: A patient in their mid 50s with DLBCL who experiences disease relapse after R-CHOP and CAR-T therapies (Dr Flowers) (54:34) CME information and select publications

Welcome back to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the world of diffused large B-cell lymphoma with special guest Dr. Carla Casulo from the Wilmot Cancer Institute in Rochester, New York. Key Points Covered: •⁠  ⁠Understanding the importance of accurate diagnosis through excisional biopsy in diffused large B-cell lymphoma. •⁠  ⁠Exploring the significance of cell of origin in guiding treatment decisions. •⁠  ⁠Initial treatment approaches for stage 1 and 2 disease, including the use of Polatuzumab based on the POLARIX trial. •⁠  ⁠Treatment options for relapsed or refractory disease, including CAR-T therapy, BiTE therapy, and anti-CD19 antibody agents. •⁠  ⁠Managing toxicities associated with different treatment regimens, such as cytopenias, infections, and neurotoxicity. Join us as we unravel the complexities of diffused large B-cell lymphoma and discuss the latest advancements in treatment options with Dr. Carla Casulo. Stay informed and up to date with the Oncology Brothers podcast! Don't forget to like, share, and subscribe for more insightful discussions on oncology topics. Thank you for tuning in to the Oncology Brothers podcast. Website: http://www.oncbrothers.com/ Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?

Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?

Gilles Salles, MD, PhD - Differentiating Decisions in Transplant-Ineligible Relapsed/Refractory DLBCL: What Are Our Options, and How Do We Choose Between Them?

Learn from the experts about aligning treatments with patient expectations at first relapse of diffuse large B-cell lymphoma (DLBCL). Credit available for this activity expires: 7/29/25 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1001321?ecd=bdc_podcast_libsyn_mscpedu

Effective communication between patients and healthcare providers is crucial to facilitate shared decision-making and meaningful dialogue that supports improved patient outcomes in diffuse large B-cell lymphoma (DLBCL) care. In this episode, CANCER BUZZ speaks with Jean Louise Koff, MD, MSc, associate professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine in Atlanta, Georgia, about fostering trust, rapport, and collaboration in the patient-provider relationship. “I think empathy is a key part of establishing a relationship between a provider and a patient. [It] helps the patient feel safe when they're dealing with what can be a very stressful and frightening situation...A phrase that I like to use: ‘Our care team is going to take care of you. We are here for you during this diagnosis, and we're going to take care of you as you move through your care plan.'” — Jean Louise Koff, MD, MSc   Jean Louise Koff, MD, MSc Associate Professor Department of Hematology and Oncology Winship Cancer Institute Emory University School of Medicine Atlanta, GA   This video podcast was produced in partnership with the Leukemia and Lymphoma Society and made possible by support from Abbvie, Genmab, and Genentech. Resources ·       Reframing the Conversation: Effective Practices for Diffuse Large B-Cell Lymphoma - ACCC ·       DLBCL Communication Roadmap - ACCC

In this JCO Article Insights episode, Alexandra Rojek provides a summary on "Anti-CD19 Chimeric Antigen Receptor T-cell therapy for Richter's Transformation: An International, Multicenter, Retrospective Study by Kittai, et al published in the Journal of Clinical Oncology March 29th, 2024.  TRANSCRIPT The guest on this podcast episode has no disclosures to declare. Alexandra Rojek: Hello and welcome to JCO Article Insights. I'm your host, Alexandra Rojek, and today we will be discussing an original report published in the June 10th issue of JCO titled, “Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study,” by Kittai et al. This report addresses the real world efficacy of CAR T-cell therapy for patients with Richter transformation of CLL to large B cell lymphoma, which represents a high risk group of patients with an unmet need for novel and more effective therapeutic agents than are currently available. Richter's represents the transformation of chronic lymphocytic leukemia, or CLL, to an aggressive lymphoma, most often a large B cell lymphoma, most similar to diffuse large B cell lymphoma or DLBCL. Treatment for Richters is often modeled after treatment practices for DLBCL. However, there's no clear standard of care and outcomes for these patients lag behind those of large B cell lymphoma patients otherwise. An important advance in recent years in the DLBCL field is the approval of anti CD19 CAR T-cell therapy in the second and third line settings. However, patients with Richter transformation were largely excluded from these pivotal trials. This study in JCO thus set out to address what the real world outcomes were for patients with Richters who were treated with CAR T-cell therapy across 12 centers internationally. The study included 69 patients across these twelve sites, with a median age of 63 years at diagnosis of Richters and a median of six years after initial CLL diagnosis. Included patients received a median of four prior lines of therapy for either CLL or Richters, with a median of two prior lines of therapy for Richters, although two patients had not received any prior therapy for their Richter transformation. The most recent prior treatments included chemoimmunotherapy in 29% of patients, followed by BTK inhibitors in 19%, as well as combinations of BTK inhibitors and BCL2 inhibitors in 12%. 17% of patients had not received prior therapy for their CLL before their diagnosis with Richters, 58% of cases had known TP53 mutations at time of transformation, and 41% exhibited deletion 17p by FISH. Prior to receiving CAR T-cell therapy, 86% of patients required additional bridging therapy, most commonly with a BTK inhibitor or chemoimmunotherapy. A diverse set of commercial CAR T-cell products were represented in this study, with the majority of patients at 64% receiving axi-cel, 25% receiving tisa-cel, 10% receiving liso-cel, and one patient received brexu-cel in an investigational setting. Median time from apheresis to CAR T infusion was 34 days, and 59% of patients continued on a BTK inhibitor throughout CAR T-cell therapy. When we move on to look at responses, 66 out of 69 patients were available for response. Three patients died related to adverse events after infusion and before response assessment, with the best overall response of complete response or CR in 46% of patients and partial response or PR in 17% for an overall response rate of 63%. With a median follow up time of 24 months, the median PFS in the study was 4.7 months and the median OS was 8.5 months. For those who achieved a CR, the median duration of response was an impressive 27 months, and for those achieving PR, the median duration of response was only two months. The two year PFS rate was thus 28%, and the two year OS rate was 38%. Four patients who achieved a CR went on to receive an allogeneic stem cell transplant. Among those whose disease progressed, 8% had relapse involving the CNS, compared to 10% of patients having CNS involvement prior to CAR T in this study population. The authors were also able to look at minimal residual disease, or MRD testing for CLL in a subset of 27 patients in this study. MRD was undetectable by PCR or flow in either blood or bone marrow in 81% of these 27 patients. However, not all of these patients had paired pre and post CAR T samples available for comparison, thus limiting more detailed interpretation. In an analysis of risk factors linked to adverse outcomes, the study authors found in a multivariable analysis for overall survival that a greater number of prior lines of therapy for Richters, a higher Ki-67 proliferation index, and a higher baseline LDH and CRP were all associated with shorter OS. They did not find an association between patterns of BTK inhibitor use, whether prior to apheresis, as a part of bridging, or concurrent with CAR T-cell therapy, to be associated with either PFS or OS. In evaluating rates of toxicities for patients with Richters treated with CAR T, the authors find that grade 3 or higher cytokine release syndrome or CRS occurred in 16% of patients and grade 3 or higher neurotoxicity or ICANS occurred in 37%. They did not find any baseline features associated with higher risk of severe CRS, however, did find that prior venetoclax exposure was associated with severe ICANS. Overall, the authors find that CAR T-cell therapy is a feasible and effective therapy for Richter transformation of CLL to large B cell lymphoma, thus contributing data to support this additional therapeutic option in a high risk patient population with unmet therapeutic needs. While the PFS and OS rates are lower than those of their large B cell lymphoma counterparts, overall response rate of 63% and particularly the CR rate of 46% with a duration of response of 27 months for this group is quite promising. Those who achieved less than a CR had a much shorter duration of response and progressed quickly, and overall, the median overall survival of the whole study population is only over eight months, which reflects the high risk and poor outcome nature of treatment for Richters with currently available therapies. As the authors discuss, it is likely that the efficacy of CAR T-cell therapy is somewhat overstated in their results by virtue of not being able to include patients who were intended for CAR T-cell therapy but could not receive it in this retrospective study. This represents one of the many real world challenges patients and clinicians treating Richters face. However, the promising results for those who were able to receive CAR T-cell therapy represent a path forward for future investigations for Richters patients. One of the avenues of future pursuit is the addition of BTK inhibitors to CAR T-cell therapy. A subset of patients included in this study received BTK inhibitors for CLL before, during, and after CAR T-cell therapy, and although limited by subgroup analysis and statistical power constraints, this study's authors did not find a difference in outcomes for those who received BTK inhibitors in these settings. Toxicities with severe CRS and ICANS were higher than rates reported in large B cell lymphoma CAR T trials. However, as the authors note, these were comparable to the study of liso-cel toxicity in CLL patients. Higher rates of infection related deaths were also noted compared to large B cell lymphoma patient counterparts, however, in line with comparable CLL patient studies and thus likely related to the unique biology of Richters arising from CLL rather than de novo large B cell lymphoma. In summary, this important work evaluating the outcomes of patients with Richter's transformation treated with anti CD19 CAR T-cell therapy in the commercial setting provides important evidence as to the efficacy of this therapy among patients with an unmet need for efficacious and novel therapies to improve outcomes. As this group of patients is often excluded from clinical trials, this data is particularly important and should drive forward future studies focusing on and or including patients with Richters, given the benefits seen for a subset of patients who achieve a response in the study. While the antecedent CLL distinguishes Richters from de novo large B cell lymphoma biologically along with differences in prior treatment regimens, this study in JCO suggests that future strategies targeting improving baseline disease factors prior to CAR T-cell therapy, including successfully bridging patients to CAR T, reducing risk of CRS and ICANS with treatment, and improving long term efficacy after CAR T with novel constructs, and CAR design, may all be promising next steps in the advancement of CAR T-cell therapy for patients with Richter transformation. This is Alexandra Rojek. Thank you for listening to JCO Article Insights. Don't forget to give us a rating or review, and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts.    The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

An experimental regimen for DLBCL piques my interest. Venetoclax ibrutinib Prednisone Obinutuzumab Revlimid (lenalidomide) Link: https://www.nejm.org/doi/pdf/10.1056/NEJMoa2401532

- Overview of Diffuse Large B-Cell Lymphoma (DLBCL), Including Staging and Grading, In the Context of COVID, Seasonal Flu and RSV - Current Standard of Care, New & Emerging Treatment Approaches - Treatment Options for Relapsed Refractory DLBCL, Including Bispecific Antibodies - Understanding How Bispecific Antibodies Work in the Treatment of Relapsed Refractory DLBCL - The Role of Clinical Trials: How Research Contributes to Treatment Options - Tips to Prevent & Manage Treatment Side Effects, Symptoms, Discomfort & Pain - Talking with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts

- Overview of Diffuse Large B-Cell Lymphoma (DLBCL), Including Staging and Grading, In the Context of COVID, Seasonal Flu and RSV - Current Standard of Care, New & Emerging Treatment Approaches - Treatment Options for Relapsed Refractory DLBCL, Including Bispecific Antibodies - Understanding How Bispecific Antibodies Work in the Treatment of Relapsed Refractory DLBCL - The Role of Clinical Trials: How Research Contributes to Treatment Options - Tips to Prevent & Manage Treatment Side Effects, Symptoms, Discomfort & Pain - Talking with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts

Dr Andrew D Zelenetz from Memorial Sloan Kettering Cancer Center in New York City discusses recent updates on available and emerging treatment strategies for various lymphomas, moderated by Dr Neil Love. Produced by Research To Practice. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayPostConf24/Lymphoma).

In this podcast episode covering the “HemOnc Pulse” Live meeting in Chicago, an expert panel explores unanswered questions in managing diffuse large B-cell lymphoma. The panelists included Grzegorz Nowakowski, MD, a Professor of Oncology and Medicine in the Division of Hematology at the Mayo Clinic; Jane Winter, MD, a Professor of Medicine in the Division of Hematology and Oncology at the Northwestern University Feinberg School of Medicine; and Alan Skarbnik, MD, Director of the Lymphoma and Chronic Lymphocytic Leukemia Program and of Experimental Therapeutics, Malignant Hematology at Novant Health.

Dr. Patel, of the Swedish Cancer Institute in Seattle, Washington, joins Chadi Nabhan, MD, MBA, FACP, on “The HemOnc Pulse” to discuss novel frontline therapies in the lymphoma space, including the bispecific antibody glofitamab. They also discuss bispecifics versus chimeric antigen receptor (CAR) T-cell therapy, fixed duration therapy and step-up dosing, and how to sequence therapy.

Audio roundup of selected biopharma industry content from Scrip over the past business week. In this episode: Galderma prepares to take on Dupixent; Pfizer's plans for Adcetris in DLBCL; Lilly's donanemab approval delayed again; the psychedelic R&D pipeline; and an interview with BMS's CDTO Greg Meyers. https://scrip.citeline.com/SC149962/Quick-Listen-Scrips-Five-MustKnow-Things

- Overview of Diffuse Large B-Cell Lymphoma - Staging and Grading - Current Standard of Care - Treatment Options for Resistant Disease - New and Emerging Treatment Approaches - The Role of Clinical Trials - How Research Contributes to Treatment Choices - Tips to Manage Treatment Side Effects, Symptoms, Discomfort and Pain - The Increasing Role of Telehealth/Telemedicine Appointments - Key Questions to Ask Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, Including Technology, Prepared List of Questions and Discussion of OpenNotes - Questions to Ask Our Panel of Experts

The year 2024 is now underway. After a busy 2023, we're now looking back at some of the oncology headlines from the new year.  Notably, we have a clinical trial hold for a lung cancer drug, a trial that showed that a CAR-T cell therapy is cost-effective — though far from cheap — for lymphoma treatment, and a novel drug that's showing promise for the treatment of myelofibrosis.  FDA Places Hold on Trial Evaluating TIL Therapy in NSCLC The Food and Drug Administration placed a clinical hold on the ongoing IOV-LUN-202 trial, evaluating LN-145 TIL for patients with non-small cell lung cancer. With the clinical hold, new patients will not be able to enroll on the trial, and those who were previously treated will continue to be monitored.  The FDA placed the hold on the trial after the death of a patient. According to the FDA, the agency has the power to request that a trial be stopped, and then the sponsor — that's the organization or company running the study — can reply via a response letter addressing the concerns. The FDA then has 30 days to respond, and potentially allow for the trial to resume.  Breyanzi Cost Effective As Second-Line R/R DLBCL Treatment Research published in the journal, Blood Advances, found that the CAR-T cell therapy, Breyanzi, was found to be a promising and cost-effective treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma — also known as DLBCL.  The study found that the incremental cost-effective ratio of the drug was just over $99,000 per quality-adjusted life-year from a health care perspective, and just over $68,000 from a societal perspective. Both these numbers are lower than the assumed social willingness to pay up to $100,000 per quality-adjusted life-year gained, as established by the American Society of Hematology.  While Breyanzi was deemed to be cost effective, CAR-T cell therapies are still far from inexpensive. In fact, the drug cost rose by 9% since its initial approval for DLBCL in 2022. In a CURE® Speaking Out® video series, Lee Greenberger, the chief scientific officer of the Leukemia & Lymphoma Society, expressed concern about the price of these drugs.    “Some of that the government is going to have to pay, some insurance is going to have to pay, but some of it the patients are going to have to pay as well. And the price tags are going to be significant. How are we going to manage that? Phase 2 Trial Shows Fibrosis Reduction in Some With Myelofibrosis Also in the blood cancer space, findings from the phase 2a trial found that a novel drug, GB2064, reduced fibrosis in the bone marrow, thereby slowing cancer progression in patients with myelofibrosis who were previously treated with Jakafi.  Myelofibrosis is a disease that affects the body's production of blood cells in the bone marrow. The disease causes scar tissue to grow there — a process called fibrosis. By decreasing the amount of fibrosis that occurs, GB2064 has the potential to improve outcomes. For this patient population. However, we should note that this trial was completed in only a small number of patients — 10, to be exact. Six patients had a decrease of fibrosis after receiving GB2064 for six months.   For more news on cancer updates, research and education, don't forget to subscribe to CURE®'s newsletters here.

Use Your Scientific or Medical Background in Medical Editing & Factchecking so you can supplement your income while working from anywhere on your own schedule. Visit learnAMAstyle.com for a free step-by-step checklist. Get immediate medical writing assistance from experienced, excellent, native-English speaking MD- and PhD-medical writers. Nascentmc.com Today's episode: FDA approves first state request to import drugs from Canada: The FDA has approved Florida's request to import certain drugs from Canada, marking the first time a state has been authorized to buy lower-cost medications in bulk from abroad.https://www.cnn.com/2024/01/05/politics/florida-canada-drug-imports-fda/index.html https://www.flgov.com/2024/01/05/florida-becomes-first-in-the-nation-to-have-canadian-drug-importation-program-approved-by-fda/ ·       5 FDA decisions to watch for: o   Donanemab from Eli Lilly, if approved, could be a significant Alzheimer's treatment, with Phase 3 trial results showing substantial cognitive and functional decline slowing. o   Resmetirom, an oral thyroid hormone receptor agonist, manufactured by Madrigal Pharmaceuticals showed promise in addressing nonalcoholic steatohepatitis (NASH), a leading cause of liver transplantation. o   Sotatercept, acquired by Merck, is being evaluated for treating pulmonary arterial hypertension (PAH) based on promising results from the Phase 3 STELLAR trial. o   Lifileucel, in a phase 3 trial for melanoma, is the first tumor-infiltrating lymphocyte (TIL) therapy for advanced melanoma. FDA's decision on lifileucel is expected by mid-February, and it offers potential as a one-time cell therapy for solid tumor cancer. o   Odronextamab, developed by Regeneron Pharmaceuticals, could become the first bispecific antibody approved for both FL and DLBCL, common non-Hodgkin lymphoma subtypes. This content was independently written by Dr. Emma Hitt Nichols, but the idea for the 5 upcoming drugs came from this article https://www.biopharmadive.com/news/5-fda-approval-decisions-watch-first-quarter-2024/703377 Use Your Scientific or Medical Background in Medical Editing & Factchecking so you can supplement your income while working from anywhere on your own schedule. Visit learnAMAstyle.com for a free step-by-step checklist. Get immediate medical writing assistance from experienced, excellent, native-English speaking MD- and PhD-medical writers. Nascentmc.com 

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!

At the 2023 American Society of Hematology (ASH) Annual Meeting in San Diego, California, Oncology Data Advisor had the privilege of speaking with many distinguished clinicians and patient advocates about their research presented at the meeting. Part 2 of this podcast series features exclusive conversations on nurse navigation to reduce socioeconomic disparities in leukemia treatment, dose reduction strategies to improve quality of life, the importance of diet in multiple myeloma, coping strategies during transplantation, and much more!

Diffuse large B-cell lymphoma (DLBCL) is an aggressive disease whose management is complex and requires open communication amongst a multidisciplinary care team. It has a high rate of relapse, with up to 40 percent of patients relapsing within the first two years after primary treatment. Management of a patient with DLBCL begins with prognostic evaluation of the disease and assessing the potential adverse effects of treatments. It should be followed by evaluations of physical, physiological, cognitive, and socio-economic status of the patient. When considering treatment options, the patient should be engaged to share their expectations and goals related to disease control and quality of life.   CANCER BUZZ spoke to Robin Atkins, RN, OCN, symptom triage nurse, Virginia Oncology Associates in Norfolk, Virginia. Listen as we discuss effective practices to support patients with diffuse large b-cell lymphoma throughout the care continuum.   “It's important to listen for meaning when talking with patients and caregivers who are undergoing cancer treatments for diffuse large b-cell lymphoma and incorporating that into the care plan.”   “Need to validate the patient perspective.”   “Shared decision-making is a two-way conversation.”   Robin Atkins, RN, OCN Symptom Triage Nurse Virginia Oncology Associates Norfolk, Virginia    Resources: Cancer Support Community Leukemia & Lymphoma Society    This project is supported by AbbVie/Genmab and Genentech.

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed: 1. Glofitamab for Relapsed/Refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36507690/ 2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/31451445/ 3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:https://pubmed.ncbi.nlm.nih.gov/36548927/ 4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:https://pubmed.ncbi.nlm.nih.gov/35803286/ 5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:https://pubmed.ncbi.nlm.nih.gov/35366963/ 6. Epcoritamab + R2 in high-risk follicular lymphoma:https://meetings.asco.org/abstracts-presentations/218265 7. Glofitamab in Mantle Cell Lymphoma:https://ashpublications.org/blood/article/140/Supplement%201/178/489039

In this FINAL episode of our DLBCL series, we build on our conversation from last week, focusing on the management of relapsed DLBCL. If you have not done so already, we recommend you check out Episode 077! Content: - Treatment with selective antibodies against CD19- How to approach relapsed disease after CAR-T - Use of BiTE therapy - Role of allo? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In our last episode, we discussed our approach to primary refractory DLBCL. This week, we start our conversation about relapsed DLBCL! This is an important and complex discussion, so we have split it into two episodes to help you follow along. If you have not done so already, we recommend you check out episode 076 for a discussion about the primary refractory setting.Content: - Approach to relapsed disease (after 12 months)- How to approach relapse with CNS involvement- Role of CAR-T vs. autologous transplant in this setting- How to approach treatment in patients who are poor candidates for auto or CAR-T** This episode is sponsored by HemOnc.org** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Dr Matthew Matasar from the Rutgers Cancer Institute of New Jersey in New York, New York, discusses the current and future role of CD20 x CD3 bispecific antibodies in the management of non-Hodgkin lymphoma. CME information and select publications here (https://www.researchtopractice.com/OncologyTodayBispecificNHL23)

This week, we pick up on our discussion about management of DLBCL, focusing on the primary refractory setting. A big part of this discussion is the role of CAR-T therapy. If you have not done so already, we highly recommend you check out episode 075 for the fundamentals of CAR-T before proceeding with this episode!Content: - Definitions for "primary refractory" vs. "relapsed" disease- How do we approach patients with primary refractory disease? - What are the treatment regimens for patients with primary refractory disease?- What is the role of CAR-T therapy? - How do we "bridge" patients to CAR-T therapy? - How do we monitor patients post CAR-T? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

How does semaglutide perform in patients with heart failure with preserved ejection fraction and obesity? Find out about this and more in today's PV Roundup podcast.

In this week's episode, we pause from our discussion about DLBCL to talk about the fundamentals of CAR-T, BiTE and autologous transplants, which will lay the foundation for subsequent discussions about DLBCL. These therapies are the talk of the town and have changed/will continue to change our approach to hematologic malignancies - definitely an episode you don't want to miss. Content: - What is CAR-T?- How are CAR-T cells manufactured?- What are commercially available CAR-T cell products? - What are side effects of CAR-T? - What is BiTE therapy?- What is the role of autologous transplants in lymphoma? ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week, we continue our conversation about DLBCL, this time focusing our attention on the management of early stage disease. In this week's episode, we delve into the management of advanced stage DLBCL. If you have not done so, we highly recommend you listen to our hemepath series before proceeding with this episode. Furthermore, if you have not listened to the introduction to DLBCL episode (https://www.thefellowoncall.com/tfocpodcast/dlbclintro) or our early stage DLBCL episode (https://www.thefellowoncall.com/tfocpodcast/dlbclearlystage), we highly recommend doing so, as we will be building on these basics this week. Content: - Reminders about diagnosis and staging - Treatment approaches to advanced staged diffuse large b-cell lyphoma- Management of double hit/high grade B-cell lymphomas- Links to important trials**This episode is sponsored by HemOnc.org** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

On this episode of The HemOnc Pulse, guest Jonathan Friedberg, MD, MMSc, a hematologic oncologist at the University of Rochester Medicine – Wilmot Cancer Institute, chats with host Dr. Chadi Nabhan on the subtle but important shift in the treatment landscape of diffuse large B-cell lymphoma (DLBCL)in the post-POLARIX trial era. The POLARIX trial, which was designed to improve upon the standard R-CHOP regimen for DLBCL treatment, investigated the potential of polatuzumab vedotin. The phase III trial ultimately resulted in the US Food and Drug Administration approving the treatment in previously untreated DLBCL, not otherwise specified, or high-grade B-cell lymphoma. The approval is for patients with an International Prognostic Index (IPI) score of two or greater. "I think that this was a robustly done randomized placebo-controlled trial that showed a small but clinically significant benefit as far as progression-free survival in patients with IPI score of two and above [in] large B cell lymphoma," he said.

This week, we continue our conversation about DLBCL, this time focusing our attention on the management of early stage disease. If you have not done so, we highly recommend you listen to our hemepath series (https://www.thefellowoncall.com/rotationguide-intro-to-hematopathology) before proceeding with this episode. Furthermore, if you have not listened to the introduction to DLBCL episode (Episode 072; https://www.thefellowoncall.com/tfocpodcast/dlbclintro), we highly recommend doing so, as we will be building on these basics this week. Content: - What is the role of PET/CT in diagnosis of DLBCL?- What is the Deauville score?- How do we approach treatment to early stage DLBCL?- What are options without radiation?- What are treatment options for older patients with early stage DLBCL? **This episode is sponsored by HemOnc.org** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

This week, we kick off a new series focusing on diffuse large B-cell lymphoma. In this first episode, we discuss the basics that everyone needs to understand before diving into the management of this disease. We highly recommend listening to our hemepath series before proceeding with this DLBCL series: https://www.thefellowoncall.com/rotationguide-intro-to-hematopathologyContent: - Approach to workup for a patient with suspected lymphoma- FNA vs. Core vs. Excisional biopsy for diagnosis- Use of PET/CT for staging- How to risk-stratify patients - "Double hit" vs. "double expressor"**This episode is sponsored by HemOnc.org** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Discussing two important lymphoma studies, POLARIX which led to the approval of Polatuzumab in DLBCL patients and SWOG S1826 comparing Nivolumab vs. BV with AVD in Hodgkin's Lymphoma patients with Dr. Jonathan Friedberg. In discussion with the lead author, Dr. Jonathan Friedberg - Director of Wilmot Cancer Institute, Professor of Medicine at University of Rochester Medical Center, and Editor-in-Chief at Journal of Clinical Oncology (JCO).